CAMBRIDGE, Mass. & PHILADELPHIA, Pa. – May 4, 2026 – Nava Therapeutics, a biotechnology company developing a new class of genetic medicines through precision RNA delivery, today announced it will present preclinical data from its lead programs at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 11–15, 2026, in Boston.